<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>0034-7418</journal-id>
<journal-title><![CDATA[Revista Colombiana de Ciencias Químico - Farmacéuticas]]></journal-title>
<abbrev-journal-title><![CDATA[Rev. colomb. cienc. quim. farm.]]></abbrev-journal-title>
<issn>0034-7418</issn>
<publisher>
<publisher-name><![CDATA[Departamento de Farmácia, Facultad de Ciencias, Universidade Nacional da Colombia]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S0034-74182023000200868</article-id>
<article-id pub-id-type="doi">10.15446/rcciquifa.v52n2.110746</article-id>
<title-group>
<article-title xml:lang="es"><![CDATA[Factores relacionados con la adherencia al tratamiento en pacientes con enfermedades crónicas no transmisibles en tres ciudades colombianas]]></article-title>
<article-title xml:lang="en"><![CDATA[Factors related to adherence to treatment in patients with chronic noncommunicable diseases in three Colombian cities]]></article-title>
<article-title xml:lang="pt"><![CDATA[Fatores relacionados à adesão ao tratamento em pacientes com doenças crônicas não transmissíveis em três cidades colombianas]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Molina de Salazar]]></surname>
<given-names><![CDATA[Dora Inés]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
<xref ref-type="aff" rid="Aaf"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Urina Triana]]></surname>
<given-names><![CDATA[Miguel]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
<xref ref-type="aff" rid="Aaf"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Abuabara-Turbay]]></surname>
<given-names><![CDATA[Jazmín]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Espinoza-Espitia]]></surname>
<given-names><![CDATA[Tatiana]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Flores-Ramírez]]></surname>
<given-names><![CDATA[Armando]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Vallejos-Narváez]]></surname>
<given-names><![CDATA[Álvaro]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Castro]]></surname>
<given-names><![CDATA[Gloria]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Universidad de Caldas  ]]></institution>
<addr-line><![CDATA[Manizales ]]></addr-line>
<country>Colombia</country>
</aff>
<aff id="Af2">
<institution><![CDATA[,Asociación IPS Internistas de Caldas  ]]></institution>
<addr-line><![CDATA[Manizales ]]></addr-line>
<country>Colombia</country>
</aff>
<aff id="Af3">
<institution><![CDATA[,Universidad Simón Bolívar  ]]></institution>
<addr-line><![CDATA[Barranquilla ]]></addr-line>
<country>Colombia</country>
</aff>
<aff id="Af4">
<institution><![CDATA[,VIAR Consulting  ]]></institution>
<addr-line><![CDATA[Bogotá D.C. ]]></addr-line>
<country>Colombia</country>
</aff>
<aff id="Af5">
<institution><![CDATA[,Megalabs Colombia  ]]></institution>
<addr-line><![CDATA[Bogotá D.C. ]]></addr-line>
<country>Colombia</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>08</month>
<year>2023</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>08</month>
<year>2023</year>
</pub-date>
<volume>52</volume>
<numero>2</numero>
<fpage>868</fpage>
<lpage>887</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://www.scielo.org.co/scielo.php?script=sci_arttext&amp;pid=S0034-74182023000200868&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.co/scielo.php?script=sci_abstract&amp;pid=S0034-74182023000200868&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.co/scielo.php?script=sci_pdf&amp;pid=S0034-74182023000200868&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="es"><p><![CDATA[ Objetivo identificar y evaluar problemas relacionados con la adherencia al tratamiento en pacientes con enfermedades no transmisibles (ENT) mediante algunas actividades de seguimiento farmacoterapéutico (SFT) utilizando la metodología Dáder.  Métodos estudio prospectivo de corte transversal en sujetos &#8805; 18 años con ENT de 3 ciudades de Colombia. Se recolectaron los datos de utilización de medicamentos mediante una encuesta virtual. Se utilizó la metodología Dáder de SFT y se clasificaron los problemas relacionados con el medicamento (PRM) y resultados negativos a la medicación (RNM) según el Tercer Consenso de Granada. Adicionalmente, se evaluó la adherencia mediante el Test de cumplimiento The Medication Adherence Questionnaire (SMAQ) y los criterios de STOPP/START en los adultos mayores. Se realizó un análisis descriptivo de los datos y con la prueba Chi-cuadrado de Pearson se evaluó la asociación entre la adherencia y el género o edad.  Resultados se evaluaron 112 sujetos con predominio del género femenino (72.3%) y edad media de 60.2±10.9. Los diagnósticos principales más frecuentes fueron hipertensión arterial (58.9%) y diabetes mellitus tipo 2 (36.6%). La mediana de medicamentos por paciente fue 5 con un rango intercuartílico (RIQ) de 3-7. El 7.25% fue no adherente y la mayoría de las veces la causa fue atribuible al paciente. No se encontró relación entre la adherencia y el género o grupo etario. Se encontraron 51 PRM y 51 RNM con propuestas para resolverlos.  Conclusión la evaluación de la adherencia farmacológica a través de programas de SFT muestra utilidad en el manejo de los pacientes con ENT.]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[ Aim To present the preliminary report of the implementation of a pharmacotherapeutic follow-up (PF) program designed to improve the adherence of patients with chronic non-communicable diseases (NCDs) using the Dáder methodology.  Methods prospective cross-sectional study in subjects &#8805; 18 years with NCDs in 3 cities from Colombia. Data on the use of medications were collected through a virtual survey. The Dáder methodology was used, and the drug-related problems (DRP) and negative outcomes associated with medication (NOM) were classified according to the Granada Third Consensus. Additionally, adherence was assessed using The Medication Adherence Questionnaire (SMAQ) and the STOPP-START criteria were evaluated among the elder adults. Data was analyzed by descriptive statistics and the association between adherence and gender or age by Pearson's chi-squared test was evaluated.  Results One hundred twelve subjects were evaluated with a predominance of female gender (72.3%) and mean age of 60.2 ± 10.9. The most encountered diagnoses were hypertension (58.9%) and type 2 diabetes mellitus (36.6%). Median number of medications per patient was 5 whit the interquartile range (IQR) 3-7. Non-adherence was identified in 7.25% and the main reason was attributable to the patient by 90%. No association between adherence and gender or age group was identified. Fifty-one DRP and 51 NOM were found with proposals to solve them.  Conclusion The evaluation of pharmacological adherence through PF programs shows utility in the management of patients with NCDs.]]></p></abstract>
<abstract abstract-type="short" xml:lang="pt"><p><![CDATA[ Objetivo identificar e avaliar problemas relacionados à adesão ao tratamento em pacientes com doenças crônicas não transmissíveis (DCNT) por meio de algumas atividades de acompanhamento farmacoterapêutico (SFT) utilizando a metodologia Dáder.  Métodos estudo transversal prospectivo em indivíduos &#8805;18 anos com DNTs de 3 cidades colombianas. Os dados de utilização de medicamentos foram coletados por meio de uma pesquisa virtual. A metodologia SFT Dader foi utilizada e os problemas relacionados com drogas (DRP) e resultados negativos de drogas (NDR) foram classificados de acordo com o Terceiro Consenso de Granada. Além disso, a adesão foi avaliada por meio do teste de conformidade Medication Adherence Questionnaire (SMAQ) e os critérios STOPP/START em adultos mais velhos. Foi realizada análise descritiva dos dados e a associação entre adesão e sexo ou idade foi avaliada com o teste Qui-quadrado de Pearson.  Resultados foram avaliados 112 sujeitos com predominância do gênero feminino (72.3%) e idade média de 60.2±10.9 anos. Os diagnósticos principais mais frequentes foram hipertensão arterial (58.9%) e diabetes mellitus tipo 2 (36.6%). O número mediano de medicamentos por paciente foi de 5 com intervalo interquartil (IQR) de 3-7. 7.25% eram não aderentes e na maioria das vezes a causa era atribuível ao paciente. Não foi encontrada relação entre adesão e sexo ou faixa etária. Foram encontrados 51 PRM e 51 RNM com propostas para os resolver.  Conclusão a avaliação da adesão farmacológica por meio de programas SFT mostra utilidade no manejo de pacientes com DCNT.]]></p></abstract>
<kwd-group>
<kwd lng="es"><![CDATA[Adherencia a la medicación]]></kwd>
<kwd lng="es"><![CDATA[seguimiento farmacoterapéutico]]></kwd>
<kwd lng="es"><![CDATA[enfermedad cardiometabólica]]></kwd>
<kwd lng="es"><![CDATA[hipertensión arterial]]></kwd>
<kwd lng="es"><![CDATA[diabetes mellitus tipo 2]]></kwd>
<kwd lng="en"><![CDATA[Adherence to medication]]></kwd>
<kwd lng="en"><![CDATA[pharmacotherapeutic follow-up]]></kwd>
<kwd lng="en"><![CDATA[cardiometabolic diseases]]></kwd>
<kwd lng="en"><![CDATA[arterial hypertension]]></kwd>
<kwd lng="en"><![CDATA[diabetes mellitus type 2]]></kwd>
<kwd lng="pt"><![CDATA[Adesão medicamentosa]]></kwd>
<kwd lng="pt"><![CDATA[acompanhamento farmacoterapêutico]]></kwd>
<kwd lng="pt"><![CDATA[doença cardiometabólica]]></kwd>
<kwd lng="pt"><![CDATA[hipertensão arterial]]></kwd>
<kwd lng="pt"><![CDATA[diabetes mellitus tipo 2]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<label>[1]</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ho]]></surname>
<given-names><![CDATA[P.M.]]></given-names>
</name>
<name>
<surname><![CDATA[Bryson]]></surname>
<given-names><![CDATA[C.L.]]></given-names>
</name>
<name>
<surname><![CDATA[Rumsfeld]]></surname>
<given-names><![CDATA[J.S.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Circulation]]></article-title>
<source><![CDATA[Circulation]]></source>
<year>2009</year>
<volume>119</volume>
<numero>23</numero>
<issue>23</issue>
<page-range>3028-35</page-range></nlm-citation>
</ref>
<ref id="B2">
<label>[2]</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Chisholm-Burns]]></surname>
<given-names><![CDATA[M.A.]]></given-names>
</name>
<name>
<surname><![CDATA[Spivey]]></surname>
<given-names><![CDATA[C.A.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[e "cost" of medication nonadherence: Consequences we cannot a ord to accept]]></article-title>
<source><![CDATA[J. Am. Pharm. Assoc.]]></source>
<year>2012</year>
<volume>52</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>823-6</page-range></nlm-citation>
</ref>
<ref id="B3">
<label>[3]</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Abegaz]]></surname>
<given-names><![CDATA[T.M.]]></given-names>
</name>
<name>
<surname><![CDATA[Shehab]]></surname>
<given-names><![CDATA[A.]]></given-names>
</name>
<name>
<surname><![CDATA[Gebreyohannes]]></surname>
<given-names><![CDATA[E.A.]]></given-names>
</name>
<name>
<surname><![CDATA[Bhagavathula]]></surname>
<given-names><![CDATA[A.S.]]></given-names>
</name>
<name>
<surname><![CDATA[Elnour]]></surname>
<given-names><![CDATA[A.A.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Nonadherence to antihypertensive drugs: A systematic review and meta-analysis]]></article-title>
<source><![CDATA[Medicine (Baltimore)]]></source>
<year>2017</year>
<volume>96</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>e5641</page-range></nlm-citation>
</ref>
<ref id="B4">
<label>[4]</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Krass]]></surname>
<given-names><![CDATA[I.]]></given-names>
</name>
<name>
<surname><![CDATA[Schieback]]></surname>
<given-names><![CDATA[P.]]></given-names>
</name>
<name>
<surname><![CDATA[Dhippayom]]></surname>
<given-names><![CDATA[T.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Adherence to diabetes medication: A systematic review]]></article-title>
<source><![CDATA[Diabet. Med.]]></source>
<year>2015</year>
<volume>32</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>725-37</page-range></nlm-citation>
</ref>
<ref id="B5">
<label>[5]</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Jin]]></surname>
<given-names><![CDATA[J.]]></given-names>
</name>
<name>
<surname><![CDATA[Sklar]]></surname>
<given-names><![CDATA[G.E.]]></given-names>
</name>
<name>
<surname><![CDATA[Oh]]></surname>
<given-names><![CDATA[V.M.S.]]></given-names>
</name>
<name>
<surname><![CDATA[Chuen]]></surname>
<given-names><![CDATA[L.S.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Factors a ecting therapeutic compliance: A review from the patient's perspective]]></article-title>
<source><![CDATA[er. Clin. Risk Manag.]]></source>
<year>2008</year>
<volume>4</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>269-86</page-range></nlm-citation>
</ref>
<ref id="B6">
<label>[6]</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Presley]]></surname>
<given-names><![CDATA[B.]]></given-names>
</name>
<name>
<surname><![CDATA[Groot]]></surname>
<given-names><![CDATA[W.]]></given-names>
</name>
<name>
<surname><![CDATA[Pavlova]]></surname>
<given-names><![CDATA[M.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Pharmacy-led interventions to improve medication adherence among adults with diabetes: A systematic review and meta-analysis]]></article-title>
<source><![CDATA[Res. Social Adm. Pharm.]]></source>
<year>2019</year>
<volume>15</volume>
<numero>9</numero>
<issue>9</issue>
<page-range>1057-67</page-range></nlm-citation>
</ref>
<ref id="B7">
<label>[7]</label><nlm-citation citation-type="journal">
<collab>Grupo de Investigación en Atención Farmacéutica Universidad de Granada</collab>
<article-title xml:lang=""><![CDATA[Seguimiento farmacoterapéutico: Método Dáder (3a revisión: 2005)]]></article-title>
<source><![CDATA[Pharmacy Practice]]></source>
<year>2006</year>
<volume>4</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>44-53</page-range></nlm-citation>
</ref>
<ref id="B8">
<label>[8]</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Escobar-Correa]]></surname>
<given-names><![CDATA[H.]]></given-names>
</name>
<name>
<surname><![CDATA[Flores-Ramírez]]></surname>
<given-names><![CDATA[A.]]></given-names>
</name>
<name>
<surname><![CDATA[Urina-Triana]]></surname>
<given-names><![CDATA[M.A.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[La importancia de la evaluación de la adherencia farmacoterapéutica en sujetos con enfermedad cardiovascular]]></article-title>
<source><![CDATA[Arch. Venez. Farmacol. Terap.]]></source>
<year>2020</year>
<volume>39</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>767-74</page-range></nlm-citation>
</ref>
<ref id="B9">
<label>[9]</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Silva]]></surname>
<given-names><![CDATA[A.C.d.S.E.]]></given-names>
</name>
<name>
<surname><![CDATA[Sousa]]></surname>
<given-names><![CDATA[D.S.d.C.]]></given-names>
</name>
<name>
<surname><![CDATA[Perraud]]></surname>
<given-names><![CDATA[E.B.d.C.]]></given-names>
</name>
<name>
<surname><![CDATA[Oliveira]]></surname>
<given-names><![CDATA[F.R.d.A.]]></given-names>
</name>
<name>
<surname><![CDATA[Martins]]></surname>
<given-names><![CDATA[B.C.C.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Pharmacotherapeutic follow-up in a respiratory intensive care unit: description and analysis of results]]></article-title>
<source><![CDATA[Einstein (Sao Paulo)]]></source>
<year>2018</year>
<volume>16</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>eAO4112</page-range></nlm-citation>
</ref>
<ref id="B10">
<label>[10]</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Herrera]]></surname>
<given-names><![CDATA[E.V.]]></given-names>
</name>
<name>
<surname><![CDATA[Cortés]]></surname>
<given-names><![CDATA[T.L.]]></given-names>
</name>
<name>
<surname><![CDATA[Valenzuela]]></surname>
<given-names><![CDATA[O.L.]]></given-names>
</name>
<name>
<surname><![CDATA[García]]></surname>
<given-names><![CDATA[E.A.]]></given-names>
</name>
<name>
<surname><![CDATA[Velázquez]]></surname>
<given-names><![CDATA[J.F.]]></given-names>
</name>
<name>
<surname><![CDATA[López]]></surname>
<given-names><![CDATA[J.G.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Aplicación del método DÁDER de Seguimiento farmacoterapéutico para pacientes con hipertrigliceridemia de la zona centro del estado de Veracruz- México]]></article-title>
<source><![CDATA[Rev. Mex. Cienc. Farm.]]></source>
<year>2012</year>
<volume>43</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>58-63</page-range></nlm-citation>
</ref>
<ref id="B11">
<label>[11]</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Guzman-Tordecilla]]></surname>
<given-names><![CDATA[D.N.]]></given-names>
</name>
<name>
<surname><![CDATA[Bernal-García]]></surname>
<given-names><![CDATA[A.]]></given-names>
</name>
<name>
<surname><![CDATA[Rodríguez]]></surname>
<given-names><![CDATA[I.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Interventions to increase the pharmacological adherence on arterial hypertension in Latin America: A systematic review]]></article-title>
<source><![CDATA[Int. J. Public Health]]></source>
<year>2020</year>
<volume>65</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>55-64</page-range></nlm-citation>
</ref>
<ref id="B12">
<label>[12]</label><nlm-citation citation-type="">
<collab>World Health Organization</collab>
<source><![CDATA[Body mass index - BMI]]></source>
<year></year>
</nlm-citation>
</ref>
<ref id="B13">
<label>[13]</label><nlm-citation citation-type="">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Sabater-Hernández]]></surname>
<given-names><![CDATA[D.]]></given-names>
</name>
<name>
<surname><![CDATA[Silva-Castro]]></surname>
<given-names><![CDATA[M.]]></given-names>
</name>
<name>
<surname><![CDATA[Faus-Dader]]></surname>
<given-names><![CDATA[M.J.]]></given-names>
</name>
</person-group>
<source><![CDATA[Método DADER. Seguimiento Farmacoterapéutico]]></source>
<year>2007</year>
<edition>3a ed.</edition>
<page-range>127</page-range><publisher-loc><![CDATA[Universidad de Granada ]]></publisher-loc>
</nlm-citation>
</ref>
<ref id="B14">
<label>[14]</label><nlm-citation citation-type="journal">
<collab>Grupo de Investigación en Atención Farmacéutica (CTS-131), Universidad de Granada (España)</collab>
<collab>Grupo de Investigación en Farmacología (CTS-164), Universidad de Granada (España)</collab>
<collab>Fundación Pharmaceutical Care España</collab>
<collab>Sociedad Española de Farmacia Comunitaria (SEFaC)</collab>
<article-title xml:lang=""><![CDATA[Tercer Consenso de Granada sobre Problemas Relacionados con Medicamentos (PRM) y Resultados Negativos asociados a la Medicación (RNM)]]></article-title>
<source><![CDATA[Ars Pharm.]]></source>
<year>2007</year>
<volume>48</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>5-17</page-range></nlm-citation>
</ref>
<ref id="B15">
<label>[15]</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Gallo-Acosta]]></surname>
<given-names><![CDATA[C.]]></given-names>
</name>
<name>
<surname><![CDATA[Vilosio]]></surname>
<given-names><![CDATA[J.O.]]></given-names>
</name>
<name>
<surname><![CDATA[Saimovici]]></surname>
<given-names><![CDATA[J.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Actualización de los criterios STOPP-START: una herramienta para la detección de medicación potencialmente inadecuada en ancianos]]></article-title>
<source><![CDATA[Actualización en la Práctica Ambulatoria]]></source>
<year>2016</year>
<volume>18</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>124-9</page-range></nlm-citation>
</ref>
<ref id="B16">
<label>[16]</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Gallagher]]></surname>
<given-names><![CDATA[P.]]></given-names>
</name>
<name>
<surname><![CDATA[O'Mahony]]></surname>
<given-names><![CDATA[D.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[STOPP (Screening Tool of Older Persons' potentially inappropriate Prescriptions): Application to acutely ill elderly patients and comparison with Beers' criteria]]></article-title>
<source><![CDATA[Age and Ageing]]></source>
<year>2008</year>
<volume>37</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>673-9</page-range></nlm-citation>
</ref>
<ref id="B17">
<label>[17]</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Selçuk]]></surname>
<given-names><![CDATA[K.T.]]></given-names>
</name>
<name>
<surname><![CDATA[Çevik]]></surname>
<given-names><![CDATA[C.]]></given-names>
</name>
<name>
<surname><![CDATA[Mercan]]></surname>
<given-names><![CDATA[Y.]]></given-names>
</name>
<name>
<surname><![CDATA[Koca]]></surname>
<given-names><![CDATA[H.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Hypertensive patients' adherence to pharmacological and non-pharmacological treatment methods, in Turkey]]></article-title>
<source><![CDATA[Int. J. Commun. Med. Public Health]]></source>
<year>2017</year>
<volume>4</volume>
<numero>8</numero>
<issue>8</issue>
<page-range>2648</page-range></nlm-citation>
</ref>
<ref id="B18">
<label>[18]</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Cordero]]></surname>
<given-names><![CDATA[A.]]></given-names>
</name>
<name>
<surname><![CDATA[Rodriguez-Padial]]></surname>
<given-names><![CDATA[L.]]></given-names>
</name>
<name>
<surname><![CDATA[Batalla]]></surname>
<given-names><![CDATA[A.]]></given-names>
</name>
<name>
<surname><![CDATA[López-Barreiro]]></surname>
<given-names><![CDATA[L.]]></given-names>
</name>
<name>
<surname><![CDATA[Torres-Calvo]]></surname>
<given-names><![CDATA[F.]]></given-names>
</name>
<name>
<surname><![CDATA[Castellano]]></surname>
<given-names><![CDATA[J.M.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Optimal pharmacological treatment and adherence to medication in secondary prevention of cardiovascular events in Spain: Results from the CAPS study]]></article-title>
<source><![CDATA[Cardiovasc. er.]]></source>
<year>2017</year>
<volume>35</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>e12240</page-range></nlm-citation>
</ref>
<ref id="B19">
<label>[19]</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Espeche]]></surname>
<given-names><![CDATA[W.G.]]></given-names>
</name>
<name>
<surname><![CDATA[Sabio]]></surname>
<given-names><![CDATA[R.]]></given-names>
</name>
<name>
<surname><![CDATA[Diaz]]></surname>
<given-names><![CDATA[A.]]></given-names>
</name>
<name>
<surname><![CDATA[Parodi]]></surname>
<given-names><![CDATA[R.]]></given-names>
</name>
<name>
<surname><![CDATA[Sisnieguez]]></surname>
<given-names><![CDATA[C.E.L.]]></given-names>
</name>
<name>
<surname><![CDATA[Flores]]></surname>
<given-names><![CDATA[R.A.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Analysis of adherence to antihypertensive drug treatment in an Argentinean cohort]]></article-title>
<source><![CDATA[Int. J. Cardiovasc. Sci.]]></source>
<year>2020</year>
<volume>33</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>272-7</page-range></nlm-citation>
</ref>
<ref id="B20">
<label>[20]</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Tavares]]></surname>
<given-names><![CDATA[N.U.L.]]></given-names>
</name>
<name>
<surname><![CDATA[Bertoldi]]></surname>
<given-names><![CDATA[A.D.]]></given-names>
</name>
<name>
<surname><![CDATA[Mengue]]></surname>
<given-names><![CDATA[S.S.]]></given-names>
</name>
<name>
<surname><![CDATA[Arrais]]></surname>
<given-names><![CDATA[P.S.D.]]></given-names>
</name>
<name>
<surname><![CDATA[Luiza]]></surname>
<given-names><![CDATA[V.L.]]></given-names>
</name>
<name>
<surname><![CDATA[Oliveira]]></surname>
<given-names><![CDATA[M.A.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Factors associated with low adherence to medicine treatment for chronic diseases in Brazil]]></article-title>
<source><![CDATA[Rev. Saude Publica]]></source>
<year>2016</year>
<volume>50</volume>
<numero>suppl 2</numero>
<issue>suppl 2</issue>
<page-range>10s</page-range></nlm-citation>
</ref>
<ref id="B21">
<label>[21]</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Machado-Alba]]></surname>
<given-names><![CDATA[J.E.]]></given-names>
</name>
<name>
<surname><![CDATA[Torres-Rodríguez]]></surname>
<given-names><![CDATA[S.]]></given-names>
</name>
<name>
<surname><![CDATA[Vallejos-Narváez]]></surname>
<given-names><![CDATA[A.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[E ectiveness the pharmaceutical care in diabetic patients]]></article-title>
<source><![CDATA[Colomb. Med.]]></source>
<year>2011</year>
<volume>42</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>72-80</page-range></nlm-citation>
</ref>
<ref id="B22">
<label>[22]</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Montalvo]]></surname>
<given-names><![CDATA[A.]]></given-names>
</name>
<name>
<surname><![CDATA[Florez-Torres]]></surname>
<given-names><![CDATA[I.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Características de los cuidadores de personas en situación de cronicidad. Cartagena (Colombia): Un estudio comparativo]]></article-title>
<source><![CDATA[Rev. Salud Uninorte]]></source>
<year>2011</year>
<volume>24</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>181-90</page-range></nlm-citation>
</ref>
<ref id="B23">
<label>[23]</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Baroletti]]></surname>
<given-names><![CDATA[S.]]></given-names>
</name>
<name>
<surname><![CDATA[Dell'Orfano]]></surname>
<given-names><![CDATA[H.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Medication adherence in cardiovascular disease]]></article-title>
<source><![CDATA[Circulation]]></source>
<year>2010</year>
<volume>121</volume>
<numero>12</numero>
<issue>12</issue>
<page-range>1455-8</page-range></nlm-citation>
</ref>
<ref id="B24">
<label>[24]</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Xu]]></surname>
<given-names><![CDATA[H.-Y.]]></given-names>
</name>
<name>
<surname><![CDATA[Yu]]></surname>
<given-names><![CDATA[Y.-J.]]></given-names>
</name>
<name>
<surname><![CDATA[Zhang]]></surname>
<given-names><![CDATA[Q.-H.]]></given-names>
</name>
<name>
<surname><![CDATA[Hu]]></surname>
<given-names><![CDATA[H.-Y.]]></given-names>
</name>
<name>
<surname><![CDATA[Li]]></surname>
<given-names><![CDATA[M.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Tailored interventions to improve medication adherence for cardiovascular diseases]]></article-title>
<source><![CDATA[Front. Pharmacol.]]></source>
<year>2020</year>
<volume>11</volume>
<page-range>510339</page-range></nlm-citation>
</ref>
<ref id="B25">
<label>[25]</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kronish]]></surname>
<given-names><![CDATA[I.M.]]></given-names>
</name>
<name>
<surname><![CDATA[Ye]]></surname>
<given-names><![CDATA[S.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Adherence to cardiovascular medications: Lessons learned and future directions]]></article-title>
<source><![CDATA[Prog. Cardiovasc. Dis.]]></source>
<year>2013</year>
<volume>55</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>590-600</page-range></nlm-citation>
</ref>
</ref-list>
</back>
</article>
